D3 Bio
Latest round
- Series B
Last raised
- Dec 2025
Total raised
- $370M
Investors
- 9
About D3 Bio
, is a biotechnology company that researches and develops therapies for tumors and immune precision. George Chen, the company's CEO, has held senior global management positions in research, drug development and administration at leading institutions such as the National Institutes of Health, and multinational pharmaceutical companies such as Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pepperl+Gene and AstraZeneca. The company develops targeted therapies for cancer and immune-related diseases, including programs advancing into clinical evaluation across major markets. Its pipeline includes candidates designed to address tumor-driving mutations and immune pathways. The company generates revenue from out-licensing agreements, milestone payments and commercialization of approved therapeutics. The company plans to accelerate global Phase III clinical studies for its lead candidate and expand development across its oncology and immunology programs.
Who invested in D3 Bio
9 investors across 3 rounds
See all investors in D3 Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about D3 Bio
Who invested in D3 Bio?
D3 Bio has 9 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has D3 Bio raised?
D3 Bio has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did D3 Bio last raise money?
D3 Bio's most recent round on record is a Series B, in Dec 2025.
What does D3 Bio do?
, is a biotechnology company that researches and develops therapies for tumors and immune precision.
Where is D3 Bio headquartered?
D3 Bio is headquartered in Wuxi, China.
Which VCs invest in companies like D3 Bio?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at D3 Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like D3 Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.